Vomiting: Clinical Trials

49 trials for Vomiting, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed. 49 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 149Completed 49
Phase 29Completed 9

Follow Vomiting: new trials by email Literature Review of Vomiting trials Research Report on Vomiting

Trials (filtered) newest first · largest first

All 49 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I PK and Safety Study of Ondansetron Inhalation Powder
LPI-1503, Matching Placebo of LPI-1503, IV Ondansetron - Postoperative Nausea and Vomiting
Phase 1CompletedLuxena Pharmaceuticals, Inc.242025-03-132026-03-27
Effect of Magnesium Sulfate on Hemodynamics on Laparoscopic Cholecystectomy Patients
Placebo, Magnesium - Hemodynamics Instability, Pain After Surgery
Phase 1 / Phase 2CompletedZiauddin University602025-01-062026-09-02
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
Glycopyrrolate, Anisodamine - Nausea and Vomiting
Phase 1 / Phase 2CompletedJie Chen1302023-10-012024-09-05
Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children
Dexamethasone, Ondansetron, Dexmedetomidine - Postoperative Nausea and Vomiting, Post Operative Pain
Phase 1CompletedTanta University42021-10-272022-04-05
Olanzapine for the Prevention of Postoperative Nausea and Vomiting
Placebo, 5 mg Olanzapine Tablets, 10 mg Olanzapine Tablets - Postoperative Nausea
Phase 1 / Phase 2CompletedAmani Hassan Abdel-Wahab1322021-03-152023-03-09
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
Cannabidiol - Lean Body Mass, Cannabis
Phase 1CompletedUniversity of Copenhagen322020-12-012023-07-24
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
QBS10072S - Astrocytoma, Brain Cancer
Phase 1CompletedQuadriga Biosciences, Inc.152020-07-202023-01-18
Study of APD421 With and Without Ondansetron
APD421, Placebo, Ondansetron - Postoperative Nausea and Vomiting
Phase 1CompletedAcacia Pharma Ltd302018-07-172018-10-01
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers
Aprepitant Capsule 125 MG, Aprepitant oral suspension 20 mg/mL - Chemotherapy-induced Nausea and Vomiting
Phase 1CompletedThe Hospital for Sick Children172017-08-102022-04-11
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Chlorpromazine Hydrochloride - Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Phase 1CompletedCycle Pharmaceuticals Ltd.202016-11-012017-11-14
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
14C-APD421 - Post-operative Nausea and Vomiting
Phase 1CompletedAcacia Pharma Ltd62016-08-012019-06-25
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
GNS Spray 0.5mg, GNS Spray 1.0mg, GNS Spray 2.0mg - Cancer
Phase 1CompletedMaxinase Life Sciences Ltd.502015-09-012016-01-08
A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
CL-108, M366, Placebo - Pain, Nausea
Phase 1CompletedCharleston Laboratories, Inc402015-06-012019-10-14
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
Rolapitant, Digoxin, Sulfasalazine - Chemotherapy-induced Nausea and Vomiting
Phase 1CompletedTesaro, Inc.1022015-05-012015-08-25
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
Rolapitant - Chemotherapy-induced Nausea and Vomiting
Phase 1CompletedTesaro, Inc.1002015-01-012015-08-25
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Rolapitant - Oral, Rolapitant - IV - Chemotherapy-induced Nausea and Vomiting
Phase 1CompletedTesaro, Inc.1382014-09-012015-08-25
Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting
Ondansetron with1:1 ORA - sweet. - Gastroenteritis
Phase 1CompletedHamad Medical Corporation402014-09-012015-06-17
How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women
Ondansetron - Postoperative Nausea
Phase 1 / Phase 2CompletedStanford University1002013-01-012015-06-01
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
granisetron transdermal system, Granisetron IV - Chemotherapy Induced Nausea and Vomiting
Phase 1CompletedKyowa Kirin Pharmaceutical Development Ltd192012-05-012024-06-17
Acupuncture Treatment for Gastroparesis: a Pilot Study
Acupuncture for gastroparesis, Acupuncture for musculoskeletal pain - Gastroparesis, Nausea
Phase 1 / Phase 2CompletedJohns Hopkins University202011-11-012016-09-02

Showing 20 of 49. Sign in to see all of them.

Narrower conditions

Nausea (23)  ·  Postoperative Nausea and Vomiting (11)  ·  Anorexia (3)  ·  Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Breast Neoplasms (2)  ·  Gastroparesis (2)  ·  Melanoma (2)  ·  Pain (2)  ·  Abdominal Pain (1)  ·  Appetitive Behavior (1)  ·  Astrocytoma (1)  ·  Cachexia (1)  ·  Cholangiocarcinoma (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (49)  ·  Signs and Symptoms (49)  ·  Signs and Symptoms, Digestive (49)  ·  Pathologic Processes (12)  ·  Postoperative Complications (11)  ·  Nausea (9)  ·  Neurologic Manifestations (7)  ·  Digestive System Diseases (6)  ·  Gastrointestinal Diseases (4)  ·  Neoplasms by Site (4)  ·  Nervous System Diseases (4)  ·  Skin Diseases (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Neoplasms (3)

Interventions

Ondansetron (14)  ·  casopitant (9)  ·  Aprepitant (6)  ·  Dexamethasone (3)  ·  Granisetron (3)  ·  Tablets (3)  ·  rolapitant (3)  ·  Ketoconazole (2)  ·  Palonosetron (2)  ·  halofantrine (2)  ·  Acupressure (1)  ·  Acupuncture Therapy (1)  ·  Cannabidiol (1)  ·  Chlorpromazine (1)  ·  Control Groups (1)

Sponsors

GlaxoSmithKline (10)  ·  Merck Sharp & Dohme LLC (6)  ·  Tesaro, Inc. (3)  ·  Acacia Pharma Ltd (2)  ·  Sandoz (2)  ·  Accenture (1)  ·  Amani Hassan Abdel-Wahab (1)  ·  Charleston Laboratories, Inc (1)  ·  Clinica Universidad de Navarra, Universidad de Navarra (1)  ·  Cycle Pharmaceuticals Ltd. (1)  ·  Duke University (1)  ·  Hamad Medical Corporation (1)  ·  Jie Chen (1)  ·  Johns Hopkins University (1)  ·  Kyowa Kirin Pharmaceutical Development Ltd (1)

Countries

United States (22)  ·  Australia (2)  ·  Canada (2)  ·  Spain (2)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  Egypt (1)  ·  India (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Pakistan (1)  ·  Saudi Arabia (1)  ·  South Africa (1)  ·  Taiwan (1)

Top investigators

Dennis Vargo, MD (3)  ·  Soran Hong, M.D. (2)  ·  Agop Y. Bedikian, MD (1)  ·  Amani H Abdel-wahab, MD (1)  ·  Anh D Dang, PhD (1)  ·  Belen Sadaba, MD, PhD (1)  ·  Bernard P Schachtel, M.D (1)  ·  Christine M. Walko, PharmD, BCOP (1)  ·  David R. Drover, MD (1)  ·  Deborah H Allen, MSN, RN, CNS, FNP-BC, AOCNP (1)  ·  Dr Asma A Salam, MBBS, FCPS (1)

Results publications

PMID 17513629, PMID 19205754, PMID 19617379, PMID 20220045, PMID 22096279, PMID 22245954, PMID 22520120, PMID 22739139, PMID 23904932, PMID 24587006, PMID 25670522, PMID 25885838, PMID 27121336, PMID 31303716, PMID 31694495, PMID 31819674, PMID 31862004, PMID 31913911, PMID 32839657, PMID 40856942

NIH funding

2008 (2), P30CA016086 (1), R43AT004489 (1)